Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CRB-913

CANYON-1

Corbus Pharmaceuticals · Phase 1 · Completed · Enrollment 254

NCT07310901

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1: PK Lead-inn/rn/rn/rn/r
Part 2: CRB-913 low dosen/rn/rn/rn/r
Part 2: CRB-913 Medium Dosen/rn/rn/rn/r
Part 2: CRB-913 High Dosen/rn/rn/rn/r
Part 2: Placebon/rn/rn/rn/r

Not shown

  • Part 1: PK Lead-in: endpoint not reported
  • Part 2: CRB-913 low dose: endpoint not reported
  • Part 2: CRB-913 Medium Dose: endpoint not reported
  • Part 2: CRB-913 High Dose: endpoint not reported
  • Part 2: Placebo: endpoint not reported